This trial studies a new way of delivering radiation to patients with diffuse midline gliomas, which may improve the outcome of the treatment and the patients' quality of life.
- Diffuse Midline Glioma, H3 K27M-Mutant
1 Primary · 5 Secondary · Reporting Duration: Up to 3 years
1 Treatment Group
Treatment (hypofractionated RT)
1 of 1
18 Total Participants · 1 Treatment Group
Primary Treatment: Hypofractionated Radiation Therapy · No Placebo Group · Phase 2
Who is running the clinical trial?
Age Any Age · All Participants · 11 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this research endeavor still accepting participants?
"This clinical trial is currently seeking participants, as per the information found on clinicaltrials.gov. The study first went live on October 6th 2021 and was most recently updated in January of 2022." - Anonymous Online Contributor
How many participants are enrolled in the current medical experiment?
"Yes, clinicaltrials.gov attests to this medical study's ongoing recruitment process that began on October 6th 2021 and was last updated on January 31st 2022. A total of 18 patients will be sought from a single location." - Anonymous Online Contributor
Has the FDA sanctioned Hypofractionated Radiation Therapy?
"Hypofractionated Radiation Therapy's safety was evaluated at a score of 2 as, while there is limited data to support its security, there are no studies yet that assess the efficacy of this treatment." - Anonymous Online Contributor